Costs & insurance

Spravato Insurance Coverage

Spravato insurance coverage can be available when your plan's clinical, authorization and provider requirements are met. The amount you owe can include separate medicine and treatment-service charges. A drug approval, prior authorization or advertised copay alone does not tell you the full cost of every visit.

Start by asking a certified treatment center to check your exact insurance. Get the medicine, observation, clinician and facility costs explained together before you schedule a course of treatment.

Find the official Spravato center route

What treatment does this coverage apply to?

Spravato is esketamine nasal spray, not an IV ketamine infusion or compounded take-home ketamine. It is given at a certified healthcare setting with monitoring rather than supplied for unsupervised home use. The current FDA Medication Guide describes its approved adult depression uses and required monitoring. FDA Medication Guide.

Do not assume a plan's Spravato policy covers a home ketamine subscription or a different nasal compound. If your quote only says “ketamine,” ask for the precise product.

Which insurance policies have a coverage pathway?

Major insurers publish criteria, but the policy must match your plan. Two current examples show why a blanket “yes” is insufficient.

Published policy checked November 17, 2026What it establishesWhat it does not establish
Aetna commercial esketamine policy 0950A precertification process with diagnosis, treatment-history, prescriber and monitoring criteriaApproval for every Aetna member or the criteria for every Medicare plan
UnitedHealthcare commercial/individual-exchange medical benefit policySeparate esketamine criteria, documentation and reauthorization requirementsYour individual deductible, network, pharmacy route or claim payment

A clinician documents whether you meet the applicable criteria. Do not change or stop treatment to “qualify,” and do not assume a checklist on a general website replaces your medical assessment.

What does prior authorization usually involve?

The clinic should identify the policy, obtain the required clinical records and submit the request. The insurer may need a documented diagnosis, prior treatment history, symptom assessments and confirmation of the treatment setting; exact requirements differ by policy.

If your records are split across practices, ask your current prescriber to help assemble a clear history. Tell the clinic which medicines and other treatments you actually tried, when and why they stopped. Let the care team handle the clinical interpretation and coding.

Ask when the decision is expected and whether an evaluation can occur before approval. Find out what you would owe for that evaluation if the medicine is denied. For continuing care, ask when reauthorization is due and who tracks it.

Check each part of the bill

The full cost can involve more than the nasal medicine.

Part of careQuestion for the center and insurer
Initial evaluationIs the clinician in network, and what is the visit cost even if treatment is unsuitable?
Esketamine medicineMedical or pharmacy benefit? Is a designated specialty pharmacy required?
Administration and observationBundled with the drug or separate? What patient cost applies?
Facility chargeDoes the site add a hospital/outpatient fee?
Continuing visitsIs each visit authorized, and when does the authorization expire?
Transport/timeWhat arrangements do I need, and what will I pay outside the medical bill?

Ask whether the first treatment's estimate reflects the deductible and whether later visits may cost a different amount. Get the clinic to distinguish a cash price from an insurance-negotiated amount and a manufacturer-assisted medicine copay.

For budget examples and a broader comparison, see Spravato cost.

Use this benefits-check script

“Please check coverage for Spravato esketamine at [center and location], using the proposed product and billing codes from my clinician. Which benefit pays for the medicine? Are the center, clinician and dispensing pharmacy in network? Has prior authorization been approved for this setting and time period?”

Then ask:

“What are my separate medicine, observation, clinician and facility charges? Is this a deductible estimate or the final expected copay? What would I owe if a claim is denied? Please provide a written estimate, authorization details and a reference number.”

This gives you a record to compare with the eventual bill. It is more useful than a general insurer logo on the clinic's homepage.

Does the “as little as $10” offer cover everything?

No. The manufacturer's commercial savings offer concerns eligible patients' medicine costs, with limits and terms; it does not itself cover observation. A separate observation rebate has its own requirements and exclusions. Government-insured patients have a different support path. Check the current SPRAVATO withMe program terms before treating an advertised amount as your bill.

If you have Medicare or Medicaid, start with your coverage and those support rules. Do not assume a commercial copay card applies. If uninsured or underinsured, ask the support program and center about available assistance and its eligibility rules; no assistance amount is guaranteed here.

What if insurance refuses approval?

Ask for the written denial and policy. A missing record, a clinical-criteria decision and a network problem call for different next steps.

Ask the clinic whether the request can be corrected or reviewed, and follow the denial notice's appeal deadlines. Request help understanding whether another certified center is in network. If the service remains unavailable, discuss other covered treatment choices with your clinician before signing a self-pay financing agreement.

If you are comparing alternative settings, use Spravato vs ketamine. An uncovered service and an ineffective treatment are not the same thing; an insurance decision alone should not determine which medicine is clinically suitable.

How we checked: Current public Aetna and UnitedHealthcare policy documents, FDA product information and manufacturer support information were reviewed November 17, 2026. We did not verify a personal benefit, submit authorization or inspect a patient bill.